Antihypertensive Medications and Diastolic Dysfunction Progression in an African American Population

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 4, 2014, Pages 269-274

  Prendergast, Heather M ^a   Dudley, Samuel ^b   Brown, Michael ^a   Daviglus, Martha ^a   Kane, John ^c   Bradshaw Bunney, E ^a   Marcucci, Jared ^a   Sanyaolu, Rasheed ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BROWN UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African American; Antihypertensive medications; Diastolic dysfunction; Progression

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; DIASTOLIC HEART FAILURE; ECHOCARDIOGRAPHY; ECHOGRAPHY; ETHNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84916593652     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0064-1     Document Type: Article

References (21)

1. Ferdinand K, Armani A. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6:67–71.
2. Garg N, Senthilkumar A, Nusair M, et al. Heart Failure with a normal left ventricular ejection fraction: epidemiology, pathophysiology, diagnosis and management. Am J Med Sci. 2013;346:129–36.
3. Shah S. Heart failure with preserved ejection fraction in African Americans. Ethn Dis. 2012;22:432–8.
4. Aljaroudi W, Thomas J, Rodriguez L. et al. Prognostic Value of diastolic dysfunction: a state of the art review. Cardiol Rev. 2014;22:79–90.
5. Von Lueder T, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013;27:171–9.
6. James P, Oparil S, Carter B, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC-8). JAMA. 2014;311:507–20.
7. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128:2309–17.
8. Prendergast H, Dudley S, Kane J, et al. Progression of left ventricular diastolic dysfunction in ethnic minorities. High Blood Press Cardiovasc Prevention. 2013. [Epub ahead of print].
9. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
10. Flack J, Sica D, Bakris G, et al. Management of high blood pressure in blacks: an update of the international society on hypertension in blacks consensus statement. Hypertension. 2010;56:780–800.
11. Ozkor M, Rahman A, Murrow J, et al. Differences in vascular nitric oxide and endothelium-derived hyperpolarizing factor bioavailability in blacks and whites. Arterioscler Thromb Vasc Biol. 2014;34:1320-27.
12. Ding Y, Vaziri N. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. JPET. 2000;292:606–9.
13. Ding Y, Vaziri N. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension. 1998;32:718–23.
14. Tabrizchi R. Amlodipine and endothelial nitric oxide synthase activity. Cardiovasc Res. 2003;53:807–9.
15. Brener S, Ivanc T, Poloszczuk R, et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis(CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J. 2006;15:1059–63.
16. Wood P, Piran S, Liu P. Diastolic heart failure: progress, treatment challenges, and prevention. Can J Cardiol. 2011;27:302–10.
17. Gradman A, Basile J, Carter B, et al. Combination therapy in hypertension. JASH. 2010;4:90–8.
18. Bruasoulis A, Agarwal V, Tousoulis D, et al. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomized controlled studies. Heart. 2014;100:317–23.
19. Joffe S, Phillips R. Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the rough. Curr Heart Fail Rep. 2013;10:157–64.
20. Glezeva N, Baugh J. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2013. Sept 5. [Epub ahead of print].
21. Glezeva N, Baugh J. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev. 2013. Sept 5. [Epub ahead of print].